Skip to main content

Table 1 Demographic and Clinical Characteristics

From: Bacterial infections in a pediatric cohort of primary and acquired complement deficiencies

Variablea

SLE/CTD

PCD

Total, n.

45

18 (C2 = 11, C6 = 3, C1 = 3, C8 = 1)

Female, n. (%)

42 (93)

5 (28)

Age (year)

14.7 (IQR: 12.8–16.4)

11.2 (IQR: 5.25–17)

Observation

 Period (year)

4.8 (IQR: 2.7–6.5)

11.2 (IQR: 5.25–17)

SLE + Nephritis, n

23

 

SLEc, n

20

 

Other CTDs, n

2

 

LOI b

 LOI 0 n. (%)

1 (2)

3 (16)

 LOI 1 n. (%)

6 (13)

 

 LOI 2 n. (%)

10 (22)

 

 LOI 3 n. (%)

5 (11)

 

 LOI 4 n. (%)

23 (51)

 

SBI, n

27

30

SBI per 100PY

12.3 (95%CI 8.6,17.4)

14.7 (95%CI 10.5,20.4)

  1. PCD Primary complement deficiency, SLE/CTD Systemic lupus erythematosus/connective tissue disease (SLEwN: with nephritis, SLE without nephritis), LOI Level of immunosuppression
  2. a For interval variables, the medians and interquartile ranges are presented. For categorical variables, the total number and percentages are presented
  3. b LOI is the level of immunosuppression: 0: Hydroxychloroquine 1: Prednisone and/or methotrexate, 2: Azathioprine, and/or mycophenolate, 3: Methylprednisolone, 4: Rituximab, cyclophosphamide and/or tacrolimus. LOI reflects the highest level of immune suppression, thus subjects may also be taking medications listed for lower levels
  4. c SLE category without nephritis includes subjects with serositis, autoimmune cytopenias, arthritis, autoimmune hepatitis, and CNS involvement including anti-neuronal antibody+without MRI changes or CNS lupus with cerebellar involvement
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096